Paxman AB (SE:PAX)
:PAX
PAX Stock Chart & Stats
kr54.40
-kr1.20(-1.81%)
At close: 4:00 PM EST
kr54.40
-kr1.20(-1.81%)
Day’s Range― - ―
52-Week Rangekr41.00 - kr85.80
Previous CloseN/A
Volume3.13K
Average Volume (3M)100.37K
Market Cap
kr1.08B
Enterprise Valuekr962.75M
Total Cash (Recent Filing)kr120.83M
Total Debt (Recent Filing)kr13.01M
Price to Earnings (P/E)―
Beta0.11
Next Earnings
May 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding23,273,417
10 Day Avg. Volume41,338
30 Day Avg. Volume100,373
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)3.05
Price to Sales (P/S)3.95
P/FCF Ratio-145.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.81
Revenue Forecast (FY)kr465.65M
Bulls Say, Bears Say
Bulls Say
Recurring Revenue ModelPaxman's business monetizes an installed medical-device base via three durable revenue streams: initial system placements (sale or lease), repeat consumable sales, and service contracts. This creates predictable, recurring demand tied to treatment volumes and installed units, supporting stable long-term cash inflows.
Sustained Revenue GrowthConsistent top-line expansion across multiple years, including continued growth in 2025, indicates enduring market adoption of Paxman's scalp-cooling systems. Structural growth stems from clinic placements and oncology treatment volumes, underpinning the company's ability to scale recurring consumable and service sales over the mid-term.
Conservative Capital StructureVery low leverage and a materially larger equity base improve solvency and give management flexibility to fund installations, R&D, or geographic expansion without heavy debt. The conservative balance sheet reduces refinancing risk and supports investment in the installed base that drives recurring revenues.
Bears Say
Sharp Gross-margin CollapseA sudden, severe gross-margin deterioration undermines the core economics of device sales and consumables. If structural (pricing, cost increases, or product mix issues), it can erode sustainable profitability, reduce funds available for reinvestment, and question the durability of historical margin levels even if revenues continue.
Weak Cash-flow QualityRepeated negative free cash flow and a drop in operating cash in 2025 indicate uneven cash conversion and higher reinvestment or working-capital needs. Over time this can constrain organic growth, force external financing or equity raises, and limit the company's ability to self-fund placements and service expansion.
Returns And Efficiency DeteriorationNegative ROE after sizeable equity expansion signals weak capital efficiency and that incremental capital is not producing returns. Persistently low or negative returns risk investor dilution concerns and may reflect structural issues in pricing, cost control, or deployment effectiveness across regions or channels.
Paxman AB News
PAX FAQ
What was Paxman AB’s price range in the past 12 months?
Paxman AB lowest stock price was kr41.00 and its highest was kr85.80 in the past 12 months.
What is Paxman AB’s market cap?
Paxman AB’s market cap is kr1.08B.
When is Paxman AB’s upcoming earnings report date?
Paxman AB’s upcoming earnings report date is May 27, 2026 which is in 49 days.
How were Paxman AB’s earnings last quarter?
Paxman AB released its earnings results on Feb 27, 2026. The company reported -kr0.4 earnings per share for the quarter, missing the consensus estimate of kr0 by -kr0.4.
Is Paxman AB overvalued?
According to Wall Street analysts Paxman AB’s price is currently Overvalued.
Does Paxman AB pay dividends?
Paxman AB does not currently pay dividends.
What is Paxman AB’s EPS estimate?
Paxman AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Paxman AB have?
Paxman AB has 23,273,417 shares outstanding.
What happened to Paxman AB’s price movement after its last earnings report?
Paxman AB reported an EPS of -kr0.4 in its last earnings report, missing expectations of kr0. Following the earnings report the stock price went up 1.594%.
Which hedge fund is a major shareholder of Paxman AB?
Currently, no hedge funds are holding shares in SE:PAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Paxman AB
Paxman AB (publ), together with its subsidiaries, develops and sells Paxman scalp cooling system to minimize hair loss in connection with chemotherapy treatment in Europe, the United States, Mexico, Japan, Oceania, rest of Asia, and South and Central America. It serves various cancer centers and hospitals. The comapny has a research collaboration agreement with National University Hospital, Singapore for the development of portable cooling and compression device. Paxman AB (publ) was founded in 1996 and is based in Karlshamn, Sweden.
PAX Earnings Call
Q4 2026
0:00 / 0:00